Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.17 USD | +5.84% | +5.57% | -83.22% |
14/05 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
10/05 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-83.22% | 14Cr | |
+18.72% | 12TCr | |
+14.53% | 11TCr | |
-2.88% | 2.4TCr | |
+2.18% | 2.26TCr | |
-10.09% | 1.82TCr | |
-41.04% | 1.68TCr | |
-11.83% | 1.62TCr | |
+1.46% | 1.34TCr | |
+24.22% | 1.13TCr |
- Stock Market
- Equities
- RAPT Stock
- News RAPT Therapeutics, Inc.
- Goldman Sachs Initiates RAPT Therapeutics at Buy With $27 Price Target